Search
Linvoseltamab
go.drugbank.com/drugs/DB17447ApprovedInvestigationalLinvoseltamab (INN), marketed as Lynozyfic™, is a bispecific human IgG4 monoclonal antibody developed by Regeneron that promotes the interaction of B-cell maturation antigen (BCMA) on multiple myeloma … Continued approval in the U.S. is contingent upon verification of clinical benefit in a confirmatory trial. [L53363]
Synonyms: human IgG4-based anti-CD3 x anti-BCMA bispecific monoclonal antibody that binds to CD3 and BCMACategories: Bispecific B Cell Maturation Antigen-directed CD3 T Cell EngagerAmbenonium
go.drugbank.com/drugs/DB01122ApprovedWithdrawnAmbenonium is a cholinesterase inhibitor. It is used in the management of myasthenia gravis.
LetibotulinumtoxinA
go.drugbank.com/drugs/DB16820Approved[L42330] It is a 900 kDa multimeric complex comprising a 150 kDa toxin, a 130 kDa non-toxic non-haemagglutinating protein, and various other haemagglutinins. … [A249920] LetibotulinumtoxinA is a type A botulinum neurotoxin produced from fermentation of _Clostridium botulinum_ strain CBFC26.
Synonyms: BoNT/A-DSCategories: Botulinum Toxins, Type ABrexucabtagene autoleucel
go.drugbank.com/drugs/DB15699ApprovedInvestigationalMantle cell lymphoma (MCL) is a heterogeneous sub-category of non-Hodgkin's lymphoma that can be classified as either an aggressive nodal or an indolent leukemic non-nodal variant. … tumour cells in the CAR T cell preparation.
Categories: Receptors, Antigen, T-Cell, CD19-Directed Genetically Modified Autologous T-cell ImmunotherapiesOritavancin
go.drugbank.com/drugs/DB04911ApprovedInvestigational[L32634] Orbactiv, the other FDA approved oritavancin product, is administered over a 3 hour infusion and contains a lower dose of 400 mg. … Oritavancin is a glycopeptide antibiotic used for the treatment of skin infections. It was developed by The Medicines Company (acquired by Novartis).
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP2C19 InhibitorsIvosidenib
go.drugbank.com/drugs/DB14568ApprovedInvestigationalIvosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. … The drug is only effective in patients with a susceptible IDH1 mutation.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexTrospium
go.drugbank.com/drugs/DB00209ApprovedInvestigationalTrospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. … [L6208] Trospium is manufactured by _Indevus Pharmaceutical Inc._ and was granted FDA approval in 2007.[L6211]
Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme InhibitorsProducts: Sanctura XR, SPASMEX 5TrenibotulinumtoxinE
go.drugbank.com/drugs/DB19082Approved[L64095] TrenibotulinumtoxinE is distinguished from the serotype A toxins that dominate this setting by its rapid onset and short duration: effects begin around 8 hours after injection, peak at day 7, … TrenibotulinumtoxinE is a botulinum neurotoxin serotype E, produced in *Clostridium botulinum*, used for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Synonyms: BOTULINUM NEUROTOXIN SEROTYPE E (BONT/E) (EB-001), BONTOXILYSIN-EVolanesorsen
go.drugbank.com/drugs/DB15067Approved[L16621] It is indicated to treat familial chylomicronemia, a genetic condition that prevents breakdown of triglycerides and chylomicrons. … [L16621] Volanesorsen was granted a conditional approval by the European Medicines Agency.[L16621]
Etafedrine
go.drugbank.com/drugs/DB11587ApprovedEthylephedrine is be formed by alkylating ephedrine with ethyl iodide. The hydrochloride is be prepared by passing hydrogen chloride through a solution of ethylephedrine in diethyl ether [F6]. … Etafedrine (INN) or ethylephedrine is a long-acting bronchodilator and has been an ingredient combined with other drugs in the brand names Nethaprin [A32757] and Dalmacol [L2568].
Synonyms: alpha-(1-(ethylmethylamino)ethyl)benzyl alcoholCategories: Adrenergic beta-2 Receptor Agonists